Reports Q4 revenue $13.05M, consensus $18.93M. “2023 was a year of substantial progress for Repare. We advanced each of the four programs in our portfolio and set the stage for meaningful data readouts and new clinical trial starts this year,” said Lloyd Segal, president and CEO of Repare. “In particular and as leaders and innovators in PKMYT1 inhibition, we look forward to data readouts across all ongoing lunresertib clinical trials in 2024 and are excited to begin a lunresertib and WEE1 combination clinical trial in partnership with Debiopharm.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RPTX:
- RPTX Upcoming Earnings Report: What to Expect?
- Repare Therapeutics doses first patient in LIONS clinical trial
- Repare Therapeutics price target lowered to $10 from $25 at H.C. Wainwright
- Repare Therapeutics Regains Rights, Ends Roche Agreement
- Repare Therapeutics to regain global rights to Camonsertib
